Houston-area med device company grosses $11.1M in recent IPO

going public

Earlier this month, Autonomix Medical went public. The company's technology is geared toward treating pain stemming from pancreatitis and pancreatic cancer. Photo via nasdaq.com

The Woodlands-based medical device company Autonomix Medical grossed more than $11.1 million in its recent IPO.

The company’s stock now trades on the NASDAQ market under the symbol AMIX. On February 1, company officials range the NASDAQ’s closing bell. The stock closed February 5 at $5.60 per share.

The NASDAQ listing “represents a pivotal moment in the growth of our [company] and a significant corporate milestone leading to what we believe will be an exciting future for Autonomix,” says Lori Bisson, the company’s CEO.

In the IPO, Autonomix sold nearly 2.24 million shares of common stock at $5 each. The gross amount raised excludes sales commissions and other expenses.

In a January 19 filing with the U.S. Securities and Exchange Commission (SEC), Autonomix had eyed gross IPO proceeds of more than $21.2 million — nearly half of what the company actually raised — from the sale of up to 4 million shares.

For the six-month period ended September 30, 2023, Autonomix tallied a net loss of $6.9 million and a deficit of nearly $30.5 million.

Outside investors BioStar Ventures (with a 15 percent pre-IPO stake) and Tricord Holdings (5.5 percent), according to SEC documents. Before the IPO, seven Autonomix executives and directors controlled 50.6 percent of the company’s common stock.

The first medical device being developed by Autonomix, founded in 2014, is a catheter-based microchip that the company says can detect and differentiate neural signals with about 3,000 times greater sensitivity than current technology.

On its website, Autonomix cites a potential $100 billion global market for its technology.

Initially, Autonomix’s technology is geared toward treating pain stemming from pancreatitis and pancreatic cancer. Other uses for the technology, protected by dozens of patents, include management of post-surgery pain, treatment of high blood pressure, and treatment of organ-related conditions.

A day after the January 29 IPO, Autonomix announced it had wrapped up an $8 million all-stock deal to regain exclusive worldwide rights for use of its technology in the cardiology sector. In December 2021, Autonomix granted a license to Impulse Medical for use of its technology for cardiac purposes. In exchange for 1.6 million Autonomix shares, Impulse sold back those rights to Autonomix.

“Regaining the cardiology rights to our innovative technology broadens our development opportunities and provides further optionality related to our development strategy moving forward. Looking ahead, we remain focused on our pancreatic cancer pain development program and are on track to commence our first-in-human clinical study this quarter,” Bisson says.

Autonomix says its catheter-based sensing technology is designed to sense neural signals associated with pain or disease and then target those nerves for treatment.

“Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness,” say the company, “and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body.”

From Your Site Articles
FibroBiologics will IPO this week. Photo via Getty Images

Houston regenerative medicine company to IPO, move toward more human trials

ready to list

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.”

O’Heeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, O’Heeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to O’Heeron, the goal in going public is to raise capital for human trials.

“We’ve had really fantastic results with animals and now we’re ready for humans,” he explained in September. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

FibroBiologics is growing with impressive speed. O’Heeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston lands $14M in latest CPRIT grants to advance cancer, lab-on-chip research

cancer funding

Thanks to a $4 million grant from the Cancer Prevention and Research Institute of Texas, the University of Houston has recruited a top-tier researcher developing AI-powered lab-on-a-chip technology for early cancer detection.

Tianhong Cui, a professor of mechanical engineering at the University of Minnesota Twin Cities and an adjunct professor of physiology and biomedical engineering at the Mayo Clinic, specializes in microelectromechanical systems and advanced manufacturing at microscale and nanoscale levels. In addition to lab-on-a-chip systems, Cui focuses on biosensors and water sensors.

Lab-on-a-chip devices deliver big results in a tiny package

The CPRIT grant supports Cui’s development of a microscale lab-on-a-chip system for early cancer detection and post-therapy monitoring.

“Lab-on-a-chip technology crams an entire lab’s worth of functions into a tiny device roughly the size of a USB stick,” according to Built In.

Common uses for the technology include medical diagnostics, point-of-care testing, and environmental monitoring.

Lab-on-a-chip work being carried out at UH and elsewhere in Houston promises to revolutionize cancer detection and treatment. For instance, Houston biotech company iBiochips, a spinout from the Houston Methodist Research Institute, makes lab-on-a-chip devices that bolster cancer detection and therapy.

Four local organizations gain $10 million in CPRIT grants

Four other Houston-area organizations received an additional $10 million in grants in CPRIT’s latest round of funding:

  • University of Texas MD Anderson Cancer Center received two $2 million grants to recruit researchers Zheqi Li of Harvard University’s Dana-Farber Cancer Institute and Nikolaos Koundouros of Weill Cornell Medicine.
  • Rice University received one $2 million grant to recruit researcher Maria Akoppyan, formerly of the University of Southern California.
  • UT Medical Branch at Galveston received one $2 million grant to recruit researcher Cristina Santarossa of Johns Hopkins University.
  • Houston-based biopharma company Pulmotect received one $2 million grant to support better outcomes for cancer patients by activating immunity in the lungs as a first line of defense against germs.

The funding was part of $35 million in new CPRIT grants for institutions and companies across Texas approved at the organization's most recent meeting. To date, CPRIT has awarded more than $4.2 billion in grants.

“These awards support research across the cancer continuum from prevention to new classes of therapeutics,” said Dr. Scott Hiebert, chief scientific officer of CPRIT, said in a news release. “The work of these investigators will impact the lives of Texans across the state.”

2 Houston high schools soar as America's best for 2026, says U.S. News

Honor Roll

Houston ISD's Carnegie Vanguard High School is standing tall as one of the 25 best high schools in America, according to U.S. News and World Report's 2026-2027 Best High Schools rankings.

DeBakey High School for Health Professions also ranks among the top 100 nationally, and 23 more Houston-area schools join them at the top of the class in Texas.

Each year, U.S. News evaluates approximately 27,000 public high schools on six factors: college readiness, college curriculum breadth, state assessment proficiency, state assessment performance, underserved student performance, and graduation rates.

The highest ranking public schools provide the best educational environments where "students demonstrated outstanding outcomes above expectations in math, reading and science state assessments, earned qualifying scores on an array of college-level exams, and graduated in high proportions."

"Every student deserves a pathway to success, and that journey often begins with selecting the right school," said LaMont Jones, Ed.D., managing editor for education at U.S. News. "The 2026-2027 Best High Schools rankings empower families with the valuable data and transparency they need to help make the best educational choices for them. We are proud to offer this essential resource to help shape the next generation of college-ready students."

Top ranking Houston schools
Carnegie Vanguard High School once again leads in Texas as the No. 2 best high school, and soared as No. 25 in U.S. News' national list of the best high schools, up from No. 42 last year.

DeBakey High School for Health Professions is the 9th best high school in Texas and ranks No. 91 nationally (down from No. 75 last year).

Three more local schools ranked among the best STEM schools in the country: Memorial High School in Spring Branch ISD (No. 86), Seven Lakes High School in Katy ISD (No. 96), and Dulles High School in Fort Bend ISD (No. 99).

In U.S. News' ranking of the best charter schools, four Houston-area schools made the top 100: Spring Branch ISD's Westchester Academy for International Studies (No. 62), Harmony School of Innovation - Katy (No. 72), Harmony School of Discovery - Houston (No. 78), and YES Prep - North Central (No. 100).

Other Houston-area schools that rank among the 100 best in Texas are:

  • No. 17 – Kerr High School, Alief ISD, Houston
  • No. 24 – Young Women's College Prep Academy, Houston ISD
  • No. 25 – Kinder High School for Performing and Visual Arts, Houston ISD
  • No. 31 – Challenge Early College High School, Houston ISD
  • No. 39 – Westchester Academy for International Studies, Spring Branch ISD, Houston
  • No. 44 – Tomball Star Academy, Tomball ISD
  • No. 45 – Harmony School of Innovation - Katy
  • No. 46 – North Houston Early College High School, Houston ISD
  • No. 51 – Eastwood Academy, Houston ISD
  • No. 52 – Seven Lakes High School, Katy ISD
  • No. 54 – Harmony School of Discovery - Houston
  • No. 55 – Energy Institute High School, Houston ISD
  • No. 56 – Spring Early College Academy, Spring ISD
  • No. 63 – Sharpstown International School, Houston ISD
  • No. 66 – YES Prep - North Central, Houston
  • No. 73 – Tompkins High School, Katy ISD
  • No. 76 – YES Prep - Southeast, Houston
  • No. 80 – Harmony School of Innovation - Sugar Land
  • No. 81 – Clements High School, Fort Bend ISD, Sugar Land
  • No. 82 – Houston Academy for International Studies, Houston ISD
  • No. 86 – Jordan High School, Katy ISD
  • No. 88 – Victory Early College High School, Aldine ISD, Houston
  • No. 96 – Clear Horizons Early College High School, Clear Creek ISD, Houston

---

This article originally appeared on CultureMap.com.

Intuitive Machines lands $600M satellite deal, NASA ‘spacecraft bus’ contract

space deals

Houston-based space infrastructure company Intuitive Machines has scored two astronomical deals.

The deals add to the company’s soaring success. As of June 30, Intuitive Machines had a record-high $1.8 billion backlog of orders, a $1.5 billion increase from the end of last year. The current backlog includes orders for more than 80 spacecraft.

The company, which went public in 2023, expects this year’s revenue to total $900 million to $1 billion. In the first half of 2026, Intuitive Machines generated nearly $393 million in revenue.

Intuitive Machines estimates its total available market is valued at more than $150 billion.

$600 million-plus deal represents ‘important milestone’

On Monday, Intuitive Machines said it picked up a $600 million-plus deal to develop three commercial satellites for an undisclosed customer over the course of about two years.

Intuitive Machines says it will design, manufacture, set up and support several spacecraft “for a critical communications infrastructure mission.”

Steve Altemus, the company’s CEO, says the deal represents “an important milestone for Intuitive Machines and reflects the confidence our customers place in our ability to deliver high-performance spacecraft for a broad range of mission needs.”

Company nails down NASA deal for ‘spacecraft bus’

A day after announcing the $600 million-plus deal, Intuitive Machines said it secured a new contract with NASA.

Intuitive Machines says NASA’s Jet Propulsion Laboratory in Southern California will use the company’s IM 300 “spacecraft bus” for an EAGLE-VSWIR Earth observation mission. The mission is scheduled to launch in 2028.

Aside from supplying the IM 300 bus, Intuitive Machines will carry out mission support services.

The low-Earth-orbit mission will be equipped with Intuitive Machines’ hyperspectral visible to shortwave infrared (VSWIR) instrument. This technology sees colors and details that aren’t visible to the human eye.

The instrument is “designed to perform surface biology and geology observations from Earth orbit while demonstrating technologies that could support future lunar and Mars exploration missions,” Intuitive Machines says.

Intuitive Machines builds mission-critical spacecraft, systems, and infrastructure for business and government customers. To date, the company has produced more than 300 spacecraft, delivered over 575 pounds of payload to the moon and launched about 100 satellites.

View All Listings